Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will participate in the Cowen 43 rd Annual Health Care Conference in Boston next month. On March 8, Akili sessions are scheduled for the ...

Akili today announced the official release of its new product, EndeavorOTC. The mobile game is a version of Akili’s similarly named, FDA-authorized EndeavorRX, built upon the same technology. But ...

In the wake of study results showing that its video-game-based treatment for symptoms of attention-deficit/hyperactivity disorder (ADHD) could be highly effective in ...

A month after announcing it was seeking strategic alternatives, Akili Interactive, maker of a video game designed to treat ADHD, said it will go private in a merger with Virtual Therapeutics. The deal ...

KIRKLAND, Wash. & BOSTON--(BUSINESS WIRE)--Virtual Therapeutics, a company focused on improving mental health at scale using engaging, immersive games, and Akili, Inc. (Nasdaq: AKLI), a leading ...

According to Akili, those improvements translate into an increased ability to stay on top of projects and tasks and to keep track of personal items. Though none of the study participants reported any ...

BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced its strategic plan to transition from a prescription to a non-prescription business model. The ...

After a rocky year, Akili Inc. received U.S. FDA clearance for use of its non-prescription product, Endeavorotc, for treatment of adults with attention deficit/hyperactivity disorder (ADHD).

Digital therapeutics company Akili is planning to merge with Virtual Therapeutics. Upon closing, the combined organization would operate as privately held Virtual Therapeutics, with Akili as a wholly ...

Akili Interactive Labs Inc. has kicked off a phase III study of its digital treatment for children with attention-deficit/hyperactivity disorder (ADHD) living in ...